Patents Examined by Golam M. Shameem
  • Patent number: 10934296
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: March 2, 2021
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C. A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C. H. M. Wijkmans
  • Patent number: 10933037
    Abstract: The present disclosure provides certain N-Acylethanolamide derivatives, and uses relating thereto.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: March 2, 2021
    Assignee: ELIEM THERAPEUTICS, INC.
    Inventor: Andrew D. Levin
  • Patent number: 10934305
    Abstract: The disclosure provides compounds of Formulae (I)-(IX). The disclosed compounds are capable of inhibiting a mammalian SHMT. Compounds of the disclosure have numerous uses, such as for treatment of cancer or autoimmune disorders.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 2, 2021
    Assignee: The Trustees of Princeton University
    Inventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
  • Patent number: 10933071
    Abstract: Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: March 2, 2021
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Dong Wang, Fang Yuan, Zhenshan Jia, Xiaobei Wang
  • Patent number: 10919850
    Abstract: Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: February 16, 2021
    Assignee: ARAXES PHARMA LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng, Tao Wu
  • Patent number: 10918642
    Abstract: The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as cancer, or diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: February 16, 2021
    Assignee: Nerviano Medical Sciences S.R.L.
    Inventors: Simona Bindi, Davide Carenzi, Ilaria Motto, Maurizio Pulici
  • Patent number: 10919900
    Abstract: The disclosure relates to aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as methods of expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides methods of synthesizing aryl hydrocarbon receptor antagonists, such as substituted imidazopyridines and imidazopyrazines, as well as kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Magenta Therapeutics Inc.
    Inventor: Arthur Glenn Romero
  • Patent number: 10913696
    Abstract: Disclosed is a fluorination method comprising providing an aryl fluorosulfonate and a fluorinating reagent to a reaction mixture; and reacting the aryl fluorosulfonate and the fluorinating reagent to provide a fluorinated aryl species. Also disclosed is a fluorination method comprising providing, a salt comprising a cation and an aryloxylate, and SO2F2 to a reaction mixture; reacting the SO2F2 and the ammonium salt to provide a fluorinated aryl species. Further disclosed a fluorination method comprising providing a compound having the structure Ar—OH to a reaction mixture; where Ar is an aryl or heteroaryl; providing SO2F2 to the reaction mixture; providing a fluorinating reagent to the reaction mixture; reacting the SO2F2, the fluorinating reagent and the compound having the structure Ar—OH to provide a fluorinated aryl species having the structure Ar—F.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: February 9, 2021
    Assignees: Dow Global Technologies LLC, The Regents of the University of Michigan
    Inventors: Melanie S. Sanford, Douglas Bland, Patrick S. Hanley, Megan A. Cismesia, Sydonie D. Schimler
  • Patent number: 10913715
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: February 9, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10906872
    Abstract: A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: February 2, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Michael C. Van Zandt, Jennifer L. Savoy
  • Patent number: 10899772
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Steven Do, Tamiko Katsumoto, Jun Liang, Naomi S. Rajapaksa, James Richard Kiefer, Jr., Liqiang Fu
  • Patent number: 10899774
    Abstract: Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Joy Drobnick, Alberto Gobbi, Tamiko Katsumoto, Naomi S. Rajapaksa, James Richard Kiefer, Jr.
  • Patent number: 10899722
    Abstract: The present invention relates to a process for the preparation of fluoroalkylnitriles and the corresponding fluoroalkyltetrazoles starting from fluorinated carboxamides.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: January 26, 2021
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Albert Schnatterer, Jan Vermehren, Edith Beckmann, Claus-Christian Haeselhoff, Tim Hammerer, Stefan Grasser
  • Patent number: 10899702
    Abstract: Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such compounds.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: January 26, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Xiang-Qun Xie, Zhiwei Feng
  • Patent number: 10899708
    Abstract: The present invention relates to a method for purifying N-substituted maleimide. More specifically, the present invention, without performing a water washing process, enables to remove organic-acid-impurities which are difficult to remove through distillation because of having similar boiling points to the N-substituted maleimide compound by utilizing solubility of organic-acid-impurities in an organic solvent used in the preparing process of the maleimide compound, and thereby, without producing washing wastewater, ensuring removal efficiency of the organic-acid-impurities equal to or similar to an N-substituted maleimide compound subjected to a water washing process.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: January 26, 2021
    Assignee: LG CHEM, LTD.
    Inventors: Joo Young Cheon, Jun Seon Choi, Ji Yeon Kim, Ki Hyuk Kang
  • Patent number: 10894805
    Abstract: This invention concerns Selective Progesterone Receptor Modulators (SPRM) in a prodrug form as well as their application in therapy. (3?, 11?,17?)-1 1-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-diene-3,17-diol (Compound 1) is one of the invention prodrugs.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: January 19, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Christian Militzer, Antje Rottmann, Andrea Wagenfeld, Horst Irlbacher
  • Patent number: 10889545
    Abstract: The present invention provides a novel crystalline form I of hydrochloride, a crystalline form II of hydrochloride, a crystalline form of succinate, a crystalline form of tartrate, a crystalline form I of fumarate and a crystalline form II of fumarate of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine. The above-described novel crystalline forms have high solubility in water and excellent stability under moisture-proof conditions and high-humidity exposure conditions, and thus can be pharmaceutically used.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: January 12, 2021
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Aeri Kim, Kwan Hyung Cho
  • Patent number: 10889553
    Abstract: The present disclosure is directed to asymmetric triazole benzamide compounds of formula (I) and formula (II), pharmaceutical compositions thereof and methods for modulating or activating a Parkin ligase The present disclosure is also directed to methods of treating and/or reducing the incidence of diseases or conditions related to the activation of Parkin ligase. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: January 12, 2021
    Assignee: NysnoBio Ireland DAC
    Inventors: Jennifer Johnston, Paul Ross Fatheree
  • Patent number: 10889555
    Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: January 12, 2021
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino
  • Patent number: 10888562
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya